VEGFA and meningioma: Additionally, the researchers recommend that the combination therapy of everolimus with bevacizumab or octreotide could be considered for PI3K-activated meningiomas, and that pharmacotherapy using bevacizumab targeting VEGF could only be considered if no further local treatment option exists.